Phase 2Suspended
Study to Evaluate the Safety, Tolerability, and Activity of CM-101 in Patients With Systemic Sclerosis (ABATE)
A Phase 2, Multicenter, Randomized, Double-Blind, Proof of Biology Study to Evaluate the Safety, Tolerability, and Activity of CM-101 in Patients With Systemic Sclerosis
- Sponsor
- ChemomAb Ltd. (Industry)
- Enrolment
- 45 planned
- Conditions
- Systemic Sclerosis
- Interventions
- 10 mg/kg CM-101; Placebo
- Ages
- adults, older adults
- Registry
- NCT06210945
From the registry
This study is designed to assess the safety and tolerability of the anti-human CCL24 monoclonal antibody CM-101 in adult patients with systemic sclerosis (SSc). Approximately 45 patients at approximately 40 sites will be randomized in a 2:1 ratio to receive either 10 mg/kg CM-101 or placebo.
Primary outcomes
- Safety and tolerability will be assessed by treatment-emergent adverse events (TEAEs)